SCHEMBL4228042

SCHEMBL4228042

O=C(/C=C/c1cnc(NC2CCN(C(=O)c3ccccc3)CC2)c(Cl)c1)NOC1CCCCO1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY2R P49146 1/20 0.41
NAMPT P43490 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CNR1 P21554 2/20 0.39
CNR2 P34972 1/20 0.39
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
PAK1 Q13153 2/20 0.38
LRRK2 Q5S007 1/20 0.36
CCNK O75909 1/20 0.36
CDK12 Q9NYV4 1/20 0.36
EPHX1 P07099 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4228045 1.00 NPY2R (0.41) NPY2RNAMPTCYP3A4CYP2C9CNR1
SCHEMBL4227795 0.95 CCNK (0.41) NPY2RCCNKCDK12CCNA2CDK2
SCHEMBL4227787 0.95 CCNK (0.41) NPY2RCCNKCDK12CCNA2CDK2
SCHEMBL4222080 0.94 BTK (0.40) NPY2RNAMPTCYP3A4CYP2C9CNR1
SCHEMBL4222084 0.94 BTK (0.40) NPY2RNAMPTCYP3A4CYP2C9CNR1
SCHEMBL4220533 0.94 PAK1 (0.45) CNR1CNR2NOS3NOS1NOS2
SCHEMBL4220540 0.94 PAK1 (0.45) CNR1CNR2NOS3NOS1NOS2
SCHEMBL4229837 0.93 L3MBTL1 (0.40) NAMPTPAK1LRRK2CCNKCDK12
SCHEMBL4229832 0.93 L3MBTL1 (0.40) NAMPTPAK1LRRK2CCNKCDK12
SCHEMBL4227443 0.92 PAK1 (0.47) NAMPTCYP2C9PAK1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557127-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2009-07-07 US disclosed
US-20090054464-A1 HDAC INHIBITOR ASTELLAS PHARMA INC. (JP) 2009-02-26 US disclosed
US-7465731-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2008-12-16 US disclosed
EP-1776357-A1 HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) Astellas Pharma Inc. (JP) 2007-04-25 EP disclosed
US-20060052599-A1 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2006-03-09 US disclosed
WO-2006016680-A1 HYDROXYAMIDE COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF HISTONE DEACETYLASE (HDAC) ASTELLAS PHARMA INC. (JP) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052599-A1 HDAC inhibitor HDAC1, HDAC2, HDAC11 NPY2R 540/4885NAMPT 2180/4885CYP3A4 2924/4885
US-20090054464-A1 HDAC INHIBITOR HDAC1, HDAC2, HDAC8 NPY2R 360/4885NAMPT 1853/4885CYP3A4 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.